Culture and identification of a “Deltamicron” SARS-CoV-2 in a three cases cluster in southern France

Competing Interest Statement

Didier Raoult has a conflict of interest as having been a consultant for Hitachi High-Technologies Corporation, Tokyo, Japan from 2018 to 2020. He is a scientific board member of Eurofins company and a founder of a microbial culture company (Culture Top). All other authors have no conflicts of interest to declare. Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Funding Statement

This work was supported by the French Government under the Investments for the Future program managed by the National Agency for Research (ANR), Mediterranee-Infection 10-IAHU-03; by Region Provence Alpes Cote d Azur and European funding FEDER PRIMMI (Fonds Europeen de Developpement Regional-Plateformes de Recherche et d'Innovation Mutualisees Mediterranee Infection), FEDER PA 0000320 PRIMMI; by Hitachi High-Technologies Corporation, Tokyo, Japan; and by the French Ministry of Higher Education, Research and Innovation (ministere de l'Enseignement superieur, de la Recherche et de l Innovation) and the French Ministry of Solidarity and Health (Ministere des Solidarites et de la Sante).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study has been approved by the ethics committee of the University Hospital Institute Mediterranee Infection (No. 2022-001). Access to the patients biological and registry data issued from the hospital information system was approved by the data protection committee of Assistance Publique-Hopitaux de Marseille (APHM) and was recorded in the European General Data Protection Regulation registry under number RGPD/APHM 2019-73.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes